Capecitabine for treating head and neck cancer

References

• Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52(1):23–47.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer J Int Du Cancer. 1999;80(6):827–841.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol: Off J Am Soc Clin Oncol. 1992;10(8):1245–1251.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase iii evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (e1395): an intergroup trial of the eastern cooperative oncology group. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(15):3562–3567.
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22(9):1743–1752.
   PubMed Web of Science ®Google Scholar
• El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol: Off J Am Soc Clin Oncol. 1996;14(3):838–847.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Mach-nc collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet (London, England). 2000;355(9208):949–955.
   PubMed Web of Science ®Google Scholar
• Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The department of veterans affairs laryngeal cancer study group. N Engl J Med. 1991;324(24):1685–1690.
   PubMed Web of Science ®Google Scholar
• Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contracts program. Cancer. 1987;60(3):301–311.
   PubMed Web of Science ®Google Scholar
• Forastiere AA. Randomized trials of induction chemotherapy. Crit Rev Hematol/Oncol Clin North Am. 1991;5(4):725–736.
   PubMed Web of Science ®Google Scholar
• Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French groupe d’etude des tumeurs de la tete et du cou (gettec). Br J Cancer. 2000;83(12):1594–1598.
   PubMed Web of Science ®Google Scholar
• Paccagnella A, Orlando A, Marchiori C, et al. Phase iii trial of initial chemotherapy in stage iii or iv head and neck cancers: a study by the gruppo di studio sui tumori della testa e del collo. J Natl Cancer Inst. 1994;86(4):265–272.
   PubMedGoogle Scholar
• Wolf GT. Commentary: phase iii trial to preserve the larynx: induction chemotherapy and radiotherapy versus concurrent chemotherapy and radiotherapy versus radiotherapy–intergroup trial r91–11. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19(18 Suppl):28s–31s.
   Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, et al. A phase iii randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol: Off J Am Soc Clin Oncol. 1992;10(2):257–263.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Johnson J, Jiminez U, et al. Phase iii trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and neck interferon cooperative study group. J Clin Oncol: Off J Am Soc Clin Oncol. 1998;16(3):1054–1059.
   PubMed Web of Science ®Google Scholar
• Schornagel JH, Verweij J, de Mulder PH, et al. Randomized phase iii trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European organization for research and treatment of cancer head and neck cancer cooperative group study. J Clin Oncol: Off J Am Soc Clin Oncol. 1995;13(7):1649–1655.
   PubMed Web of Science ®Google Scholar
• Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Eortc early clinical trials group. Ann Oncol: Off J Eur Soc Med Oncol /ESMO. 1994;5(6):533–537.
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol: Off J Am Soc Clin Oncol. 1996;14(5):1672–1678.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol. 2005;17(3):218–224.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase ii evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an eastern cooperative oncology group trial (pa390). Cancer. 1998;82(11):2270–2274.
   PubMed Web of Science ®Google Scholar
• Smith RE, Thornton DE, Allen J. A phase ii trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995;22(3 Suppl 6):41–46.
   PubMed Web of Science ®Google Scholar
• Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(17):2644–2652.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lee J, Urba S, et al. A phase ii trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010;28(9):910–916.
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Lammerts van Bueren JJ, Van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173(7):4699–4707.
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Phase iii randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(34):8646–8654.
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Cohn A, Varkey JA, et al. Phase ii study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20(1):160–164.
   PubMed Web of Science ®Google Scholar
• Morant R, Bernhard J, Dietrich D, et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase ii trial. Br J Cancer. 2004;90(7):1312–1317.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase iii trial results. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20(12):2812–2823.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Halabi S, Rini B, et al. A phase ii study of gemcitabine and capecitabine in metastatic renal cancer: a report of cancer and leukemia group b protocol 90008. Cancer. 2006;107(6):1273–1279.
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203–2206.
   PubMed Web of Science ®Google Scholar
• Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. Cancer. 1992;70(4 Suppl):998–1002.
   PubMed Web of Science ®Google Scholar
• Adjei AA. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol. 1999;48(3):265–277.
   PubMed Web of Science ®Google Scholar
• Bunnell CA, Winer EP. Oral 5-fu analogues in the treatment of breast cancer. Oncology (Williston Park, NY). 1998;12(10 Suppl 7):39–43.
   PubMed Web of Science ®Google Scholar
• Diasio RB. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 1999;58(Suppl 3):119–126.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Royce M, Medgyesy D, et al. Oral fluoropoyrimidines. Semin Oncol. 1999;26(6):640–646.
   PubMed Web of Science ®Google Scholar
• Macdonald JS. Oral fluoropyrimidines: a closer look at their toxicities. Am J Clin Oncol. 1999;22(5):475–480.
   PubMed Web of Science ®Google Scholar
• Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer (Oxford, England: 1990). 1998;34(10):1509–1513.
   PubMed Web of Science ®Google Scholar
• Rustum YM, Cao S. New drugs in therapy of colorectal cancer: preclinical studies. Semin Oncol. 1999;26(6):612–620.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Xeloda Colorectal Cancer Study Group. J Clin Oncol. 2001;1;19(21):4097–4106.
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;30;352(26):2696–2704.
   Web of Science ®Google Scholar
• Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol: Off J Am Soc Clin Oncol. 1998;16(5):1795–1802.
   PubMed Web of Science ®Google Scholar
• Venturini M. Rational development of capecitabine. Eur J Cancer (Oxford, England: 1990. 2002;38(Suppl 2):3–9.
   PubMedGoogle Scholar
• Folkman J. What is the role of thymidine phosphorylase in tumor angiogenesis. J Natl Cancer Inst. 1996;88(16):1091–1092.
   PubMedGoogle Scholar
• Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338(6216):557–562.
   PubMed Web of Science ®Google Scholar
• Sumizawa T, Furukawa T, Haraguchi M, et al. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem. 1993;114(1):9–14.
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A. 1995;92(4):998–1002.
   PubMed Web of Science ®Google Scholar
• Toi M, Hoshina S, Taniguchi T, et al. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer J Int Du Cancer. 1995;64(2):79–82.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine,n4-pentyloxycarbonyl-5ʹ-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull. 1998;21(7):713–717.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase ii study. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22(12):2321–2327.
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79(3–4):627–630.
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nat Clin Pract Oncol. 2009;6(1):17–24.
   PubMedGoogle Scholar
• Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85–104.
   PubMed Web of Science ®Google Scholar
• Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14c-labelled drug. Invest New Drugs. 1999;17(1):49–56.
   PubMed Web of Science ®Google Scholar
• Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res: off J Am Assoc Cancer Res. 1999;5(7):1696–1702.
   PubMed Web of Science ®Google Scholar
• Frings S. Capecitabine a novel oral tumour-activated fluoro-pyrimidine. Onkologie. 1998;21:451–458.
   Google Scholar
• Martinez-Trufero J, Isla D, Adansa JC, et al. Phase ii study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer. 2010;102(12):1687–1691.
   PubMed Web of Science ®Google Scholar
• Bentzen JD, Hansen HS. Phase ii analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head & Neck. 2007;29(1):47–51.
   PubMed Web of Science ®Google Scholar
• Won YW, Park YH, Ahn MJ, et al. A phase ii study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol: Off J Eur Soc Med Oncol /ESMO. 2011;22(2):417–423.
   PubMed Web of Science ®Google Scholar
• Yeo W, Leung TW, Chan AT, et al. A phase ii study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer (Oxford, England: 1990). 1998;34(13):2027–2031.
   PubMed Web of Science ®Google Scholar
• Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase ii study. Ann Oncol: Off J Eur Soc Med Oncol /ESMO. 2002;13(8):1252–1258.
   PubMed Web of Science ®Google Scholar
• Tan EH, Khoo KS, Wee J, et al. Phase ii trial of a paclitaxel and carboplatin combination in asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 1999;10(2):235–237.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Tannock IF, Degendorfer P, et al. A phase ii trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002;38(7):686–690.
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol. 2005;28(5):464–471.
   PubMed Web of Science ®Google Scholar
• Wang CC, Chang JY, Liu TW, et al. Phase ii study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head & Neck. 2006;28(1):74–80.
   PubMed Web of Science ®Google Scholar
• Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase ii trial using a triplet combination. Cancer. 2005;103(3):569–575.
   PubMed Web of Science ®Google Scholar
• Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial npc-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328–1338.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Kim DH, et al. Phase ii study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2005;93(10):1117–1121.
   PubMed Web of Science ®Google Scholar
• Ahn D, Kim JH, Sohn JH, et al. Laryngeal preservation in stage iii/iv resectable laryngo-hypopharyngeal squamous cell carcinoma following concurrent chemoradiotherapy with capecitabine/cisplatin. Mole Clin Oncol. 2013;1(4):685–691.
   PubMedGoogle Scholar
• Chua DTT, Sham JST, Au GKH. A phase ii study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003;39(4):361–366.
   PubMed Web of Science ®Google Scholar
• Chua D, Wei WI, Sham JS, et al. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol. 2008;38(4):244–249.
   PubMed Web of Science ®Google Scholar
• Sykes AJ, Slevin NJ, MacDougall RH, et al. Results of a phase i study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2004;71(1):81–84.
   PubMed Web of Science ®Google Scholar
• Gupta S, Khan H, Barik S, et al. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer. Drug Discov Ther. 2013;7(1):36–42.
   PubMedGoogle Scholar
• Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012;136(3):777–788.
   PubMed Web of Science ®Google Scholar
• El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast. 2005;14(5):368–374.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Kaufmann M, Siedentopf F, et al. Capecitabine monotherapy: review of studies in first-line her-2-negative metastatic breast cancer. The Oncologist. 2012;17(4):476–484.
   PubMed Web of Science ®Google Scholar
• Cassidy J. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–575.
   PubMed Web of Science ®Google Scholar
• Nutley NR. Pharmaceuticals: Xeloda (capecitabine) [product information] In. 2003.
   Google Scholar
• Li Z, Jiang N, Xu Y. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy. Australas J Dermatol. 2016;57(1):e14–16.
   Google Scholar
• Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011;10(2):159–169.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics Annex I. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000316/WC500058151.pdf.
   Google Scholar
• Becker K, Erckenbrecht JF, Haussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57(4):475–484.
   PubMed Web of Science ®Google Scholar
• Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. The Oncologist. 2001;6(1):56–64.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Twelves C, Breddy J, et al. Capecitabine named-patient programme for patients with advanced breast cancer. The UK experience. Eur J Cancer (Oxford, England: 1990). 2002;38(15):2020–2024.
   PubMed Web of Science ®Google Scholar
• Evans TR, Pentheroudakis G, Paul J, et al. A phase i and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol: Off J Eur Soc Med Oncol /ESMO. 2002;13(9):1469–1478.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Weiss GR, Burris HA, et al. Phase i and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol: Off J Am Soc Clin Oncol. 1999;17(6):1915–1925.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Dirix L, Bissett D, et al. A phase i study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res: off J Am Assoc Cancer Res. 1998;4(11):2755–2761.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337–1345.
   PubMed Web of Science ®Google Scholar
• Okamoto E, Osaki M, Kase S, et al. Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas. Pathol Int. 2001;51(3):158–164.
   PubMed Web of Science ®Google Scholar
• Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331–344.
   PubMed Web of Science ®Google Scholar